← Leaderboards
Christian L. Lorson
University Of Missouri-Columbia
$14,535,349
Attributed
$17,297,648
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,297,648 · 15
By mechanism
R01$7,130,365 · 4
G20$5,667,997 · 1
R21$3,364,793 · 7
R33$718,096 · 1
R56$383,397 · 1
R13$33,000 · 1
Top collaborators
- Elliot J Androphy5 shared
- Kevin Hodgetts5 shared
- Monique A Lorson5 shared
- Hansjorg Rindt2 shared
- Monir Shababi2 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Monique A Lorson$1,775,607
- Monir Shababi$203,038
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsSpinal Muscular AtrophyMotor NeuronsDesignGenesRna SplicingGeneticMolecularMouse ModelLeadPhenotypeNeurodegenerative DisordersMutationDefectSmn2 GenePreventExonsTranscriptBaseMutantRegulationGenetic TranscriptionLengthAlternative Splicing
Grant awards (44)
Understanding the role of patient-derived Ighmbp2 mutations in neurodegeneration and pre-rRNA processing$559,861
R01 · FY2025 · NS · contact PI
Understanding the role of patient-derived Ighmbp2 mutations in neurodegeneration and pre-rRNA processing$622,078
R01 · FY2024 · NS · contact PI
Novel SMARD1 Mouse Models: Characterization and Evaluation of Potential Therapeutic Targets$337,776
R01 · FY2024 · NS · contact PI
Novel SMARD1 Mouse Models: Characterization and Evaluation of Potential Therapeutic Targets$347,706
R01 · FY2023 · NS · contact PI
Improvements to the Regional Biocontainment Research Facilities at the University of Missouri$2,340,729
G20 · FY2022 · AI · contact PI
Novel SMARD1 Mouse Models: Characterization and Evaluation of Potential Therapeutic Targets$347,706
R01 · FY2022 · NS · contact PI
Improvements to the Regional Biocontainment Research Facilities at the University of Missouri$3,327,268
G20 · FY2021 · AI · contact PI
Novel SMARD1 Mouse Models: Characterization and Evaluation of Potential Therapeutic Targets$347,189
R01 · FY2021 · NS · contact PI
Novel SMARD1 Mouse Models: Characterization and Evaluation of Potential Therapeutic Targets$338,654
R01 · FY2020 · NS · contact PI
Identification of modifiers of the neurodegenerative phenotype in nmd mice$406,213
R21 · FY2019 · NS · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$212,328
R33 · FY2019 · NS
IGHMBP2 patient-derived missense mutations: large animal models of SMARD1$193,750
R21 · FY2019 · NS · contact PI
Identification of SMA modifying genes$187,150
R21 · FY2019 · NS · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$505,768
R33 · FY2018 · NS
IGHMBP2 patient-derived missense mutations: large animal models of SMARD1$232,500
R21 · FY2018 · NS · contact PI
Identification of SMA modifying genes$225,900
R21 · FY2018 · NS · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$431,954
R21 · FY2016 · NS
Optimization of a novel series of thiazolopyridines for the treatment of SMA$420,850
R21 · FY2016 · NS
Evaluating AAV-mediated gene replacement for Spinal Muscular Atrophy with Respiratory Distress 1$183,850
R21 · FY2016 · NS · contact PI
Optimization of a novel series of thiazolopyridines for the treatment of SMA$447,563
R21 · FY2015 · NS
Evaluating AAV-mediated gene replacement for Spinal Muscular Atrophy with Respiratory Distress 1$222,225
R21 · FY2015 · NS · contact PI
Determinants that regulate splicing of SMN$383,397
R56 · FY2012 · NS · contact PI
Stimulating SMN2 exon 7 inclusion with short RNAs$254,036
R01 · FY2011 · HD · contact PI
Monoallelic repair of expanded huntingtin by trans-splicing$185,588
R21 · FY2011 · NS · contact PI
Stimulating SMN2 exon 7 inclusion with short RNAs$256,602
R01 · FY2010 · HD · contact PI
Monoallelic repair of expanded huntingtin by trans-splicing$227,250
R21 · FY2010 · NS · contact PI
Determinants that regulate splicing of SMN$109,939
R01 · FY2010 · NS · contact PI
Stimulating SMN2 exon 7 inclusion with short RNAs$259,194
R01 · FY2009 · HD · contact PI
Determinants that regulate splicing of SMN$111,050
R01 · FY2009 · NS · contact PI
Determinants that regulate splicing of SMN$326,620
R01 · FY2008 · NS · contact PI
Stimulating SMN2 exon 7 inclusion with short RNAs$302,489
R01 · FY2008 · HD · contact PI
Funding for FightSMA Researchers' Conference in Washington, DC, April 2008$33,000
R13 · FY2008 · NS · contact PI
Determinants that regulate splicing of SMN$326,620
R01 · FY2007 · NS · contact PI
Stimulating SMN2 exon 7 inclusion with short RNAs$308,741
R01 · FY2007 · HD · contact PI
Determinants that regulate splicing of SMN$71,646
R01 · FY2007 · NS · contact PI
Determinants that regulate splicing of SMN$35,000
R01 · FY2007 · NS · contact PI
Determinants that regulate splicing of SMN$336,375
R01 · FY2006 · NS · contact PI
Determinants that regulate splicing of SMN$343,256
R01 · FY2004 · NS
Determinants that regulate splicing of SMN$91,233
R01 · FY2004 · NS
Determinants that regulate splicing of SMN$362,483
R01 · FY2003 · NS
Determinants that regulate splicing of SMN$89,506
R01 · FY2003 · NS
Determinants that regulate splicing of SMN$323,838
R01 · FY2002 · NS
Determinants that regulate splicing of SMN$228,750
R01 · FY2001 · NS
Determinants that regulate splicing of SMN$92,017
R01 · FY2001 · NS